Kristine Heidemeyer

Dr. Kristine Heidemeyer

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LFLaurence Feldmeyer
Laurence Feldmeyer
KHKristine Heidemeyer
Kristine Heidemeyer
NYNikhil Yawalkar
Nikhil Yawalkar
Acute generalized exanthematous pustulosis (AGEP) is a severe, usually drug-related reaction, characterized by an acute onset of mainly small non-follicular pustules on an erythematous base and spontaneous resolution usually within two weeks. Systemic involvement occurs in about 20% of cases. The course is mostly benign, and only in rare cases complications lead to life-threatening situations. Recent studies highlight the importance of genetic variations in interleukin-36 receptor antagonist gene (IL-36RN) in the pathogenesis of this disease. The physiopathology of AGEP remains unclear, but an involvement of innate and acquired immune cells together with resident cells (keratinocytes), which recruit and activate neutrophils via production of cytokines/chemokines such as IL-17, IL-36, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNFα) and chemokine (C-X-C motif) ligand 8 (CXCL8)/IL-8, has been postulated. Treatment is based on the removal of the causative drug, supportive care, infection prevention and use of potent topical or systemic steroids.

4 August 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MLM. Lehmann
M. Lehmann
PSP. Schorno
P. Schorno
RHR.E. Hunger
R.E. Hunger
KHKristine Heidemeyer
Kristine Heidemeyer
LFL. Feldmeyer
L. Feldmeyer
NYNikhil Yawalkar
Nikhil Yawalkar
Click on the article title to read more.

17 October 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
SBSimon Bossart
Simon Bossart
CDCloé Daneluzzi
Cloé Daneluzzi
SCSimone Cazzaniga
Simone Cazzaniga
ARAlbert‐Adrien Ramelet
Albert‐Adrien Ramelet
HUHeiko Uthoff
Heiko Uthoff
TWTorsten Willenberg
Torsten Willenberg

18 April 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
ASAndrea Sechi
Andrea Sechi
JSJunhyuk Song
Junhyuk Song
MDMassimo Dell'ANtonia
Massimo Dell'ANtonia
KHKristine Heidemeyer
Kristine Heidemeyer
Bianca Maria PiracciniBianca Maria Piraccini
Bianca Maria Piraccini
LNLuigi Naldi
Luigi Naldi
Recently, the impressive efficacy of JAK‐inhibitors (JAK‐I) in alopecia areata (AA) has been described in several studies; however, to date, there is limited information on the safety of JAK‐I in AA patients. For this reason, on 18 August 2022, a systematic review was performed to collect the premarketing and postmarketing data on the safety of JAK‐I in patients treated for AA, evaluating for each molecule the reported adverse events (AEs) in indexed literature and their frequency. The keywords ‘alopecia areata’ AND ‘Jak‐inhibitors OR Janus‐kinase Inhibitors’ were searched on PubMed, Embase and Cochrane databases.Of 407 studies retrieved, 28 papers met the requirements and were used in our review, including five RCTs and 23 case series; overall, 1719 patients were included, and the safety of 6 JAK‐I was assessed (baricitinib, brepocitinib, deuruxolitinib, ritlecitinib, ruxolitinib and tofacitinib). Systemic JAK‐I were well‐tolerated, most of the AEs were mild, and the withdrawal rate for AEs was very low and inferior to placebo in controlled studies (1.6% vs. 2.2%). Laboratory abnormalities represented 40.1% of AEs associated with oral JAK‐I, which mostly included the rise in cholesterol, transaminase, triglycerides, creatine phosphokinase (CPK) and sporadic cases of neutro/lymphocytopenia. The remaining AEs involved the respiratory tract (20.8%), the skin (17.2%), the urogenital (3.8%), or the gastroenterological (3.4%) tract. Increased rates of infections involved not only the upper (19.0%) and lower (0.3%) respiratory tract, but also the urogenital system (3.6%) and the skin (4.6%). Isolated cases of grade 3 to 4 AEs have been reported, including myocardial infarction, hypertensive urgencies, cellulitis, rhabdomyolysis, neutropenia and high elevation of creatinine kinase. No fatal outcomes were reported. AEs reported with topical formulation included scalp irritation and folliculitis.The main limit of this review is the lack of data related to postmarketing surveillance, which should be maintained on a long‐term basis.

1 September 2023 in Psoriasis: Targets and Therapy
Verified
Journal Article
Open access
PDF file
KHKristine Heidemeyer
Kristine Heidemeyer
MLMarco May Lee
Marco May Lee
SCSimone Cazzaniga
Simone Cazzaniga
NYNikhil Yawalkar
Nikhil Yawalkar
LNLuigi Naldi
Luigi Naldi
Palmoplantar pustulosis (PPP) is a chronic, relapsing, inflammatory disease that can occur alone or in association with arthritis. There is still controversy about whether it should be separated from psoriasis or classified as pustular psoriasis. Furthermore, drug-induced paradoxical PPP is a special variant of PPP that differs from classic PPP in several ways. Treatment of PPP is still challenging, and there are a number of treatment-resistant cases. This review summarizes the risk factors for the development of PPP and the currently available treatment modalities. Female sex, smokers or ex-smokers, obesity, thyroid dysfunction, and treatment with a tumor necrosis factor (TNF)-α inhibitor have been identified as risk factors for the disease’s development, severity, and course. Topical treatments and phototherapy are effective for some patients and are used as a first-line or adjuvant treatment modality. Conventional treatments including retinoids and fumaric acid show good effects and can increase the efficacy of treatment with psoralen + ultraviolet light therapy (PUVA). Ciclosporin is fast acting, but relapse mostly occurs immediately after cessation. TNF-α inhibitors are efficient, and an even better response can be achieved with IL-17 and IL-23 blockers as well as apremilast. The effect of Janus kinase inhibitors seems to be promising according to case reports, but further investigations with larger cohorts are needed.

15 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SBSimon Bossart
Simon Bossart
CDCloé Daneluzzi
Cloé Daneluzzi
MMMatthias B. Moor
Matthias B. Moor
CHCédric Hirzel
Cédric Hirzel
KHKristine Heidemeyer
Kristine Heidemeyer
DSDaniel Sidler
Daniel Sidler
CSCC (cutaneous squamous cell carcinoma) and its precursors are a major cause of morbidity, especially in immunosuppressed patients, and are frequently associated with human papillomavirus (HPV) infections. The purpose of this study is to investigate the therapeutic potential of alpha-HPV vaccination for immunosuppressed patients with established cSCC and its precursors. In this retrospective study, all patients who received Gardasil-9®, a nonavalent HPV vaccine, as secondary prophylaxis were examined. Dermatologic interventions in both the pre- and post-vaccination periods were analyzed with zero-inflated Poisson regression and a proportional intensity model for repeated events with consideration of the clinically relevant cofactors. The hazard ratio for major dermatologic interventions was 0.27 (CI 0.14–0.51, p < 0.001) between pre- and post-Gardasil-9® intervention. Gardasil-9® vaccination showed good efficacy in reducing major dermatologic interventions even after correction of relevant cofactors and national COVID-19 caseloads during the observational period. Alpha-HPV vaccination may potentially cause a significant decrease in dermatologic interventions and overall mortality as well as healthcare costs in immunosuppressed patients with high skin tumor burden.